Suppr超能文献

经前瞻性研究的数字液滴 PCR 评估,血清 miR371 在睾丸生殖细胞癌去势前后的表达。

Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study.

机构信息

Mohn Cancer Research Laboratory, Department of Oncology and Medical Physics, Haukeland University Hospital, Jonas Lies vei 91B, 5021, Bergen, Norway.

Department of Urology and CLINTEC Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

出版信息

Sci Rep. 2021 Aug 2;11(1):15582. doi: 10.1038/s41598-021-94812-2.

Abstract

MicroRNA-371a-3p (miR371) has been suggested as a sensitive biomarker in testicular germ cell cancer (TGCC). We aimed to compare miR371 with the classical biomarkers α-fetoprotein (AFP) and β-human chorionic gonadotropin (hCG). Overall, 180 patients were prospectively enrolled in the study, with serum samples collected before and after orchiectomy. We compared the use of digital droplet PCR (RT-ddPCR) with the quantitative PCR used by others for detection of miR371. The novel RT-ddPCR protocol showed high performance in detection of miR371 in serum samples. In the study cohort, miR371 was measured using RT-ddPCR. MiR371 detected CS1 of the seminoma and the non-seminoma sub-types with a sensitivity of 87% and 89%, respectively. The total sensitivity was 89%. After orchiectomy, miR371 levels declined in 154 of 159 TGCC cases. The ratio of miR371 pre- and post-orchiectomy was 20.5 in CS1 compared to 6.5 in systemic disease. AFP and hCG had sensitivities of 52% and 51% in the non-seminomas. MiR371 is a sensitive marker that performs better than the classical markers in all sub-types and clinical stages. Especially for the seminomas CS1, the high sensitivity of miR371 in detecting TGCC cells may have clinical implications.

摘要

微小 RNA-371a-3p(miR371)已被认为是睾丸生殖细胞癌(TGCC)的敏感生物标志物。我们旨在比较 miR371 与经典生物标志物甲胎蛋白(AFP)和β-人绒毛膜促性腺激素(hCG)。总体而言,180 名患者前瞻性纳入本研究,在睾丸切除术前后采集血清样本。我们比较了数字液滴 PCR(RT-ddPCR)与其他人用于检测 miR371 的定量 PCR 的使用。新的 RT-ddPCR 方案在血清样本中检测 miR371 时表现出高性能。在研究队列中,使用 RT-ddPCR 测量了 miR371。miR371 检测精原细胞瘤和非精原细胞瘤亚类的 CS1 的灵敏度分别为 87%和 89%。总灵敏度为 89%。睾丸切除术切除后,159 例 TGCC 病例中的 154 例 miR371 水平下降。CS1 中 miR371 术前与术后的比值为 20.5,全身疾病为 6.5。AFP 和 hCG 在非精原细胞瘤中的灵敏度分别为 52%和 51%。miR371 是一种敏感标志物,在所有亚类和临床阶段的表现均优于经典标志物。特别是对于精原细胞瘤 CS1,miR371 检测 TGCC 细胞的高灵敏度可能具有临床意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2915/8329070/b6ce5880e6ae/41598_2021_94812_Fig1_HTML.jpg

相似文献

3
microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients.
Cell Oncol (Dordr). 2017 Aug;40(4):379-388. doi: 10.1007/s13402-017-0333-9. Epub 2017 Jun 13.
4
Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management.
J Urol. 2021 Jan;205(1):137-144. doi: 10.1097/JU.0000000000001337. Epub 2020 Aug 28.
5
MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker.
Andrology. 2015 Jan;3(1):78-84. doi: 10.1111/j.2047-2927.2014.00269.x. Epub 2014 Sep 4.
10
Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?
J Cancer Res Clin Oncol. 2017 Nov;143(11):2383-2392. doi: 10.1007/s00432-017-2490-7. Epub 2017 Aug 17.

引用本文的文献

1
MicroRNA-371-373 cluster extracellular vesicle-based communication in testicular germ cell tumors.
Cell Commun Signal. 2025 May 30;23(1):252. doi: 10.1186/s12964-025-02250-8.
2
Potential next generation markers of testicular germ cell tumors: miRNA-371a-3p.
Int Urol Nephrol. 2025 Mar;57(3):691-700. doi: 10.1007/s11255-024-04284-2. Epub 2024 Nov 22.
3
Perioperative Serum MicroRNA 371a-3p and 372-3p Levels in Patients with Clinically Localized Testicular Masses.
Eur Urol Open Sci. 2024 Aug 17;68:1-9. doi: 10.1016/j.euros.2024.08.003. eCollection 2024 Oct.
6
MicroRNA-371a-3p-The Novel Serum Biomarker in Testicular Germ Cell Tumors.
Cancers (Basel). 2023 Aug 3;15(15):3944. doi: 10.3390/cancers15153944.
7
Refining the serum miR-371a-3p test for viable germ cell tumor detection.
Sci Rep. 2023 Jun 29;13(1):10558. doi: 10.1038/s41598-023-37271-1.
10
Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence.
Front Oncol. 2022 Dec 8;12:1056823. doi: 10.3389/fonc.2022.1056823. eCollection 2022.

本文引用的文献

1
Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin.
J Cancer Res Clin Oncol. 2021 Feb;147(2):435-443. doi: 10.1007/s00432-020-03429-x. Epub 2020 Nov 16.
4
6
Quantitative PCR Measurement of miR-371a-3p and miR-372-p Is Influenced by Hemolysis.
Front Genet. 2019 May 22;10:463. doi: 10.3389/fgene.2019.00463. eCollection 2019.
9
Clinical utility of plasma miR-371a-3p in germ cell tumors.
J Cell Mol Med. 2019 Feb;23(2):1128-1136. doi: 10.1111/jcmm.14013. Epub 2018 Dec 7.
10
Applying Standard Clinical Chemistry Assay Validation to Droplet Digital PCR Quantitative Liquid Biopsy Testing.
Clin Chem. 2018 Dec;64(12):1732-1742. doi: 10.1373/clinchem.2018.291278. Epub 2018 Sep 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验